
Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker


Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a partnership with Life Line Screening (LLS), a

<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/QTRX">QTRX</a>), today announced a partnership with <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifelinescreening.com%2F%3Fsrsltid%3DAfmBOooi7lIsJfsaBfEd2rcb9lNZ64fnHH0mo83C6bfrw_PzkK4_avah%26sourcecd%3DWNAT001&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=Life+Line+Screening+%28LLS%29&amp;index=1&amp;md5=b4223d3563e01605c0f4f369a5994806" shape="rect">Life Line Screening (LLS)</a>, a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both organizations to provide non-invasive, easily accessible testing in the general public.

</p><p xmlns="http://www.w3.org/1999/xhtml">
According to the Alzheimer&#39;s Association, an estimated 7 million Americans are living with Alzheimer&#39;s disease today, with another 6-7 million experiencing symptoms of Mild Cognitive Impairment (MCI). These figures underscore the urgent public health need for scalable testing options that can facilitate earlier identification of the disease in its most treatable phase.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Too many chronic conditions go undetected until they become life-altering events," said Jim Waters, Chief Operating Officer at LLS. "By partnering with Lucent Diagnostics, we&#39;re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it's something we're excited to bring to communities across the country."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Now available to their network, LLS can continue its mission by bringing cutting edge blood tests in an accessible and convenient way. Through their mobile delivery model, LLS will provide testing opportunities in local venues such as community centers, churches, and senior centers. The results of these tests can then be shared to help primary care physicians facilitate early intervention and proactive lifestyle management for adults.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Scientific rigor shouldn't stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer's Disease," says Zachary Fernandes, Quanterix General Manager for Lucent Diagnostics.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Life Line Screening is a national provider operating in the 48 contiguous states. By hosting over 15,000 community events annually, they provide a scalable infrastructure that reaches individuals in both major metropolitan areas and underserved rural regions. To learn more about LLS, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifelinescreening.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.lifelinescreening.com&amp;index=2&amp;md5=aeb8fd97eee0ed6e52b36522a5fb5bce" shape="rect">www.lifelinescreening.com</a>. To learn more about Lucent Diagnostics and Quanterix, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lucentdiagnostics.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.lucentdiagnostics.com&amp;index=3&amp;md5=1200f9aaa1ef454685a096423709058b" shape="rect">www.lucentdiagnostics.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Lucent Diagnostics
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver revolutionary tools that aid in the earlier detection of cognitive disease. Powered by the ultra-sensitive Simoa<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. With more than a decade of proven success within the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.LucentDiagnostics.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.LucentDiagnostics.com&amp;index=4&amp;md5=6c5be676b6eacc478fed6ff609116d0e" shape="rect">www.LucentDiagnostics.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Life Line Screening Partners
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Established in 1993, Life Line Screening is the nation's leading provider of community-based preventive health screenings. The Company has empowered more than 11 million people to understand their health risks and take proactive steps toward maintaining their well-being. Life Line Screening serves over 15,000 locations across the US annually.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260302958140r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260302958140/en/" rel="nofollow">https://www.businesswire.com/news/home/20260302958140/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Quanterix Media Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@quanterix.com" shape="rect">media@quanterix.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Joshua Young
<br xmlns="http://www.w3.org/1999/xhtml"></br>(508) 846-3327 - mobile
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:jyoung@quanterix.com" shape="rect">jyoung@quanterix.com</a>    

</p>

QTRX

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

Quanterix Expands Testing Access Through Life Line Screening Partnership

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker


Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:QTRX), today announced a partnership with Life Line Screening (LLS), a</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Quanterix Corporation&#039;s Lucent Diagnostics has partnered with Life Line Screening to provide accessible blood tests for early detection of Alzheimer&#039;s disease. This collaboration could significantly enhance diagnostic capabilities and increase demand for Quanterix&#039;s innovative biomarker tests in community healthcare settings.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Lucent Diagnostics partners with Life Line Screening to launch blood tests.</li><li>Tests aim for earlier detection of Alzheimer&#039;s disease and related conditions.</li><li>Partnership enhances accessibility through community health venues.</li><li>7 million Americans have Alzheimer&#039;s, highlighting urgent need for testing.</li><li>Lucent Diagnostics employs ultra-sensitive technology for reliable results.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Quanterix Corporation (QTRX)</strong>: Parent company of Lucent Diagnostics, leveraging new partnerships to drive growth.</li><li><strong>Life Line Screening (LLS)</strong>: Key partner expanding Quanterix&#039;s biomarker tests into community healthcare.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This falls under &#039;Corporate Developments&#039; as it involves strategic partnerships enhancing Quanterix&#039;s access to new markets and revenue streams. The collaboration is crucial for building broader awareness and application of its technology in community health settings.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Expansion into community healthcare could boost revenue for Quanterix significantly.</li><li>Increased testing for Alzheimer&#039;s may enhance market positioning for related technologies.</li><li>Strategic partnerships like this could lead to higher demand and sales growth for QTRX.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>7 million Americans currently live with Alzheimer&#039;s disease.</li><li>Lucent Diagnostics was established in 2023 to support cognitive disease detection.</li><li>Life Line Screening hosts over 15,000 events annually across the US.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Invest in QTRX for potential growth from increased test availability and demand.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml" class="bwalignc">
<i xmlns="http://www.w3.org/1999/xhtml">Collaboration Aims to Expand Access to Early Detection of Potential Disease Marker</i>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/QTRX">QTRX</a>), today announced a partnership with <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifelinescreening.com%2F%3Fsrsltid%3DAfmBOooi7lIsJfsaBfEd2rcb9lNZ64fnHH0mo83C6bfrw_PzkK4_avah%26sourcecd%3DWNAT001&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=Life+Line+Screening+%28LLS%29&amp;index=1&amp;md5=b4223d3563e01605c0f4f369a5994806" shape="rect">Life Line Screening (LLS)</a>, a national organization focused on identifying asymptomatic risks for chronic conditions in community health settings. Through the partnership, Life Line Screening will offer Lucent's non-invasive blood based biomarker test nationally, with programs in Florida, California, and Texas already underway. This partnership supports the goals of both organizations to provide non-invasive, easily accessible testing in the general public.

</p><p xmlns="http://www.w3.org/1999/xhtml">
According to the Alzheimer&#39;s Association, an estimated 7 million Americans are living with Alzheimer&#39;s disease today, with another 6-7 million experiencing symptoms of Mild Cognitive Impairment (MCI). These figures underscore the urgent public health need for scalable testing options that can facilitate earlier identification of the disease in its most treatable phase.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Too many chronic conditions go undetected until they become life-altering events," said Jim Waters, Chief Operating Officer at LLS. "By partnering with Lucent Diagnostics, we&#39;re able to continue to expand our mission of uncovering asymptomatic risks earlier and more equitably. This partnership has the potential to impact numerous lives by supporting more informed treatment pathways, and it's something we're excited to bring to communities across the country."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Now available to their network, LLS can continue its mission by bringing cutting edge blood tests in an accessible and convenient way. Through their mobile delivery model, LLS will provide testing opportunities in local venues such as community centers, churches, and senior centers. The results of these tests can then be shared to help primary care physicians facilitate early intervention and proactive lifestyle management for adults.

</p><p xmlns="http://www.w3.org/1999/xhtml">
"Scientific rigor shouldn't stop at the laboratory door. Through LLS, Lucent Diagnostics is bringing validated, high-quality science into community testing networks, helping ensure that everyone has access to information for use by their physician and not only in a research setting. This is a critical step toward earlier, more reliable detection of Alzheimer's Disease," says Zachary Fernandes, Quanterix General Manager for Lucent Diagnostics.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Life Line Screening is a national provider operating in the 48 contiguous states. By hosting over 15,000 community events annually, they provide a scalable infrastructure that reaches individuals in both major metropolitan areas and underserved rural regions. To learn more about LLS, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lifelinescreening.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.lifelinescreening.com&amp;index=2&amp;md5=aeb8fd97eee0ed6e52b36522a5fb5bce" shape="rect">www.lifelinescreening.com</a>. To learn more about Lucent Diagnostics and Quanterix, visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.lucentdiagnostics.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.lucentdiagnostics.com&amp;index=3&amp;md5=1200f9aaa1ef454685a096423709058b" shape="rect">www.lucentdiagnostics.com</a>.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Lucent Diagnostics
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Lucent Diagnostics, a commercial brand of Quanterix, was created in 2023 to deliver revolutionary tools that aid in the earlier detection of cognitive disease. Powered by the ultra-sensitive Simoa<sup xmlns="http://www.w3.org/1999/xhtml">&#xAE;</sup> technology, Lucent Diagnostics bridges the gap between research and clinical use by offering products and services designed specifically to meet the separate needs of institutions and healthcare providers. With more than a decade of proven success within the neurology research space, supported by thousands of publications and partnerships, Quanterix aims to directly impact the landscape of cognitive disease through its commercial brand, Lucent Diagnostics. For more information, please visit <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.LucentDiagnostics.com&amp;esheet=54436179&amp;newsitemid=20260302958140&amp;lan=en-US&amp;anchor=www.LucentDiagnostics.com&amp;index=4&amp;md5=6c5be676b6eacc478fed6ff609116d0e" shape="rect">www.LucentDiagnostics.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">About Life Line Screening Partners
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>Established in 1993, Life Line Screening is the nation's leading provider of community-based preventive health screenings. The Company has empowered more than 11 million people to understand their health risks and take proactive steps toward maintaining their well-being. Life Line Screening serves over 15,000 locations across the US annually.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Forward-Looking Statements
<br xmlns="http://www.w3.org/1999/xhtml"></br></b>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260302958140r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260302958140/en/" rel="nofollow">https://www.businesswire.com/news/home/20260302958140/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Quanterix Media Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:media@quanterix.com" shape="rect">media@quanterix.com</a>

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">Investor Relations Contact: 
</b><br xmlns="http://www.w3.org/1999/xhtml"></br>Joshua Young
<br xmlns="http://www.w3.org/1999/xhtml"></br>(508) 846-3327 - mobile
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:jyoung@quanterix.com" shape="rect">jyoung@quanterix.com</a>    

</p>

Quanterix Corporation's Lucent Diagnostics has partnered with Life Line Screening to provide accessible blood tests for early detection of Alzheimer's disease. This collaboration could significantly enhance diagnostic capabilities and increase demand for Quanterix's innovative biomarker tests in community healthcare settings.

Lucent Diagnostics and Life Line Screening Partner to Bring Advanced Blood-Based Diagnostics to Communities Nationwide

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News